In this opening segment on advanced renal cell carcinoma, Dr. Ornstein introduces the evolving frontline treatment landscape, highlighting the expanded role of immune checkpoint inhibitor–based combinations and VEGF receptor targeted therapies.
Evolving Treatment Strategies and Sequencing Decisions in Advanced Renal Cell Carcinoma
In this segment on advanced renal cell carcinoma, Dr. Ornstein guides the discussion toward differentiating available frontline treatment options, focusing on the choice between dual immune checkpoint inhibitor therapy and combinations of immunotherapy with VEGF receptor targeted therapies.
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline IO-Combos, Next-Generation ADCs: Evolutions in Endometrial Cancer
2
Reprogramming T Cells: The Promise of In Vivo Site-Specific CAR Engineering
3
FDA Grants Fast-Track Designation to FRα ADC in Advanced PROC
4
Lifesaving Upgrades: Reviewing 40 Years of FDA Oncology Approvals
5